![Kamran Alam](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kamran Alam
Director of Finance/CFO at
TAYSHA GENE THERAPIES, INC.
Net worth: 8 M $ as of 2026-05-30
Profile
Kamran Alam is currently Chief Financial Officer & Secretary at Taysha Gene Therapies, Inc. since 2020.
Former positions include Chief Financial Officer & Senior Vice President at Rocket Pharmaceuticals, Inc. from 2019 to 2020, Vice President-Finance at Novartis Gene Therapies, Inc. from 2016 to 2019, Senior Director-Finance & Accounting at Aptinyx, Inc. from 2013 to 2016, and Finance Director at Naurex, Inc. Education includes an undergraduate degree from Stephen M.
Ross School of Business and an MBA from Kelley School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-30 | 1,341,600 ( 0.49% ) | 8 M $ | 2026-05-30 |
Kamran Alam active positions
| Companies | Position | Start |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Director of Finance/CFO | 2020-07-31 |
Former positions of Kamran Alam
| Companies | Position | End |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Director of Finance/CFO | 2020-06-30 |
| AVEXIS INC | Corporate Officer/Principal | 2019-09-30 |
| APTINYX | Comptroller/Controller/Auditor | 2016-03-31 |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage company, which develops novel therapies | Corporate Officer/Principal | - |
Training of Kamran Alam
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
22
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage company, which develops novel therapies | Health Technology |
Stephen M. Ross School of Business
 Stephen M. Ross School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
Aptinyx, Inc.
 Aptinyx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies to treat disorders of the brain and nervous system | Health Technology |
Rocket Pharmaceuticals, Inc.
 Rocket Pharmaceuticals, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Taysha Gene Therapies, Inc.
 Taysha Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes adeno-associated viruses-based gene therapies for the treatment of monogenic diseases of the central nervous system | Health Technology |
- Stock Market
- Insiders
- Kamran Alam
